Analyst raises DexCom’s target to $88, citing improved visibility into long-term pipeline and sustained top-line growth.
Piper Sandler increased its price target for DexCom (NASDAQ:DXCM) to $88 from $75 while maintaining an Overweight rating. The adjustment follows updated models aligning with quarterly cadence, company guidance, and consensus estimates.
DexCom recently secured FDA clearance for its Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor for children aged two and older. The FDA had previously approved the device for adults in March 2024.
TD Cowen also raised its price target for DexCom to $95 from $75, highlighting the company’s leadership in type 2 diabetes coverage expansion and payer datasets.